

EZETIMIBE (Ezetrol®) for the prevention of cardiovascular events

G
R
E
Y

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of EZETIMIBE (Ezetrol®) for the prevention of cardiovascular events in patients with cholesterol levels within target range

Ezetimibe has recently been licensed for reducing the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) when added to ongoing statin therapy or initiated concomitantly with a statin.

The Pan Mersey Area Prescribing Committee (APC) does not currently recommend the addition of ezetimibe to statin treatment in patients with CHD and ACS in patients with cholesterol levels within target range. This recommendation will be reviewed if a formal application for use is received.

Prescribers should continue to prescribe ezetimibe for the management of hypercholesterolaemia in accordance with current local and national recommendations:

- > Pan Mersey APC policy statement: Ezetimibe for hypercholesterolaemia (March 2016)
<http://www.panmerseyapc.nhs.uk/recommendations/documents/PS137.pdf>
- > [NICE TA385](#): Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (February 2016)
- > [NICE CG181](#): Cardiovascular disease: risk assessment and reduction, including lipid modification (July 2014)
- > UKMi [NICE Bites No. 65](#): Lipid modification (July 2014)

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.